Fluidigm Corporation (FLDM) Downgraded by ValuEngine to Strong Sell

ValuEngine downgraded shares of Fluidigm Corporation (NASDAQ:FLDM) from a sell rating to a strong sell rating in a research note released on Thursday.

Shares of Fluidigm Corporation (NASDAQ FLDM) traded up $0.02 during midday trading on Thursday, reaching $5.24. 110,400 shares of the company were exchanged, compared to its average volume of 323,140. Fluidigm Corporation has a one year low of $2.52 and a one year high of $8.69. The company has a debt-to-equity ratio of 5.00, a current ratio of 3.02 and a quick ratio of 1.76.

COPYRIGHT VIOLATION WARNING: “Fluidigm Corporation (FLDM) Downgraded by ValuEngine to Strong Sell” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/11/12/fluidigm-corporation-fldm-downgraded-by-valuengine-to-strong-sell.html.

In other Fluidigm Corporation news, insider Levin Capital Strategies, L.P. purchased 60,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was bought at an average cost of $5.25 per share, with a total value of $315,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last three months, insiders have purchased 491,998 shares of company stock valued at $2,353,092. 4.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of FLDM. Wells Fargo & Company MN raised its holdings in Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after buying an additional 3,327 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Fluidigm Corporation by 20.5% in the first quarter. Bank of New York Mellon Corp now owns 206,578 shares of the medical research company’s stock worth $1,175,000 after buying an additional 35,176 shares during the last quarter. American International Group Inc. raised its holdings in Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares during the last quarter. Wellington Management Group LLP raised its holdings in Fluidigm Corporation by 2.4% in the first quarter. Wellington Management Group LLP now owns 630,277 shares of the medical research company’s stock worth $3,587,000 after buying an additional 14,814 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Fluidigm Corporation by 1.7% in the first quarter. Vanguard Group Inc. now owns 1,181,883 shares of the medical research company’s stock worth $6,725,000 after buying an additional 19,669 shares during the last quarter. 88.57% of the stock is owned by institutional investors and hedge funds.

About Fluidigm Corporation

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply